Nature Communications (Jun 2016)
Integrated genetic and pharmacologic interrogation of rare cancers
- Andrew L. Hong,
- Yuen-Yi Tseng,
- Glenn S. Cowley,
- Oliver Jonas,
- Jaime H. Cheah,
- Bryan D. Kynnap,
- Mihir B. Doshi,
- Coyin Oh,
- Stephanie C. Meyer,
- Alanna J. Church,
- Shubhroz Gill,
- Craig M. Bielski,
- Paula Keskula,
- Alma Imamovic,
- Sara Howell,
- Gregory V. Kryukov,
- Paul A. Clemons,
- Aviad Tsherniak,
- Francisca Vazquez,
- Brian D. Crompton,
- Alykhan F. Shamji,
- Carlos Rodriguez-Galindo,
- Katherine A. Janeway,
- Charles W. M. Roberts,
- Kimberly Stegmaier,
- Paul van Hummelen,
- Michael J. Cima,
- Robert S. Langer,
- Levi A. Garraway,
- Stuart L. Schreiber,
- David E. Root,
- William C. Hahn,
- Jesse S. Boehm
Affiliations
- Andrew L. Hong
- Boston Children’s Hospital
- Yuen-Yi Tseng
- Broad Institute of Harvard and MIT
- Glenn S. Cowley
- Broad Institute of Harvard and MIT
- Oliver Jonas
- Koch Institute for Integrative Cancer Research at MIT
- Jaime H. Cheah
- Koch Institute for Integrative Cancer Research at MIT
- Bryan D. Kynnap
- Dana-Farber Cancer Institute
- Mihir B. Doshi
- Dana-Farber Cancer Institute
- Coyin Oh
- Broad Institute of Harvard and MIT
- Stephanie C. Meyer
- Boston Children’s Hospital
- Alanna J. Church
- Boston Children’s Hospital
- Shubhroz Gill
- Broad Institute of Harvard and MIT
- Craig M. Bielski
- Broad Institute of Harvard and MIT
- Paula Keskula
- Broad Institute of Harvard and MIT
- Alma Imamovic
- Dana-Farber Cancer Institute
- Sara Howell
- Broad Institute of Harvard and MIT
- Gregory V. Kryukov
- Broad Institute of Harvard and MIT
- Paul A. Clemons
- Broad Institute of Harvard and MIT
- Aviad Tsherniak
- Broad Institute of Harvard and MIT
- Francisca Vazquez
- Broad Institute of Harvard and MIT
- Brian D. Crompton
- Boston Children’s Hospital
- Alykhan F. Shamji
- Broad Institute of Harvard and MIT
- Carlos Rodriguez-Galindo
- Boston Children’s Hospital
- Katherine A. Janeway
- Boston Children’s Hospital
- Charles W. M. Roberts
- Boston Children’s Hospital
- Kimberly Stegmaier
- Boston Children’s Hospital
- Paul van Hummelen
- Dana-Farber Cancer Institute
- Michael J. Cima
- Koch Institute for Integrative Cancer Research at MIT
- Robert S. Langer
- Koch Institute for Integrative Cancer Research at MIT
- Levi A. Garraway
- Dana-Farber Cancer Institute
- Stuart L. Schreiber
- Broad Institute of Harvard and MIT
- David E. Root
- Broad Institute of Harvard and MIT
- William C. Hahn
- Dana-Farber Cancer Institute
- Jesse S. Boehm
- Broad Institute of Harvard and MIT
- DOI
- https://doi.org/10.1038/ncomms11987
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 9
Abstract
Identifying therapeutic targets in rare cancers is challenging due to the lack of relevant pre-clinical models. Here, the authors generate a cancer cell line from a paediatric patient with a rare undifferentiated sarcoma and through functional genomics and chemical screens identified CDK4 and XPO1 as potential therapeutic targets in this cancer.
